Clinically meaningful adverse reactions of moderate to severe intensity occurring in less than 1% (< 1/ 100) of adult patients in all Phase II and III trials treated with the 500 mg/ 200 mg tipranavir/ ritonavir dose (n=1397) are listed below by system organ class and frequency according to the following categories: